

Boston Scientific announces new developments in its Electrophysiology portfolio

Boston Scientific is leading the way in developing innovative cardiac rhythm management technologies, designed to improve health outcomes for patients suffering from arrhythmias. Just recently, the first ever patient in Europe was treated with the new innovative RHYTHMIA™ Mapping System at Hammersmith Hospital in London. The RHYTHMIA™ System uses state-of-the-art 3-D technology to collect thousands of relevant data points in only a few minutes, providing Electrophysiologists with high-resolution electro-anatomical maps for use in the treatment of heart rhythm disorders.

This milestone procedure follows the inclusion of the S-ICD™ System in the recent ESC guidelines on hypertrophic cardiomyopathy (HCM), as a first-line treatment option in patients at risk of sudden cardiac arrest. Trudie Lobban, Founder and CEO of Arrhythmia Alliance, commented:

“With 75,000 to 100,000 lives lost to sudden cardiac arrest each year in the UK, there is a strong need to ensure that people suffering from arrhythmia have access to innovative medical devices like the S-ICD™ System. We welcome the inclusion of the S-ICD™ System in the recent ESC guidelines on hypertrophic cardiomyopathy (HCM), and it is important that we continue to work with stakeholders to ensure people suffering from arrhythmia in the UK benefit from this life-saving device.

There is also a need to improve diagnosis and shorten procedure times in patients with complicated heart rhythm disorders. Innovations like the RHYTHMIA™ Mapping System which improves patient care whilst providing clinicians with more accurate and detailed information are particularly welcome. We are delighted to hear that the first patient in Europe was recently treated with the RHYTHMIA™ Mapping System and we will work to ensure as many people benefit from this unique system as possible”.

These developments come ahead of the 2014 Heart Rhythm Congress in Birmingham on 5-8 October 2014, where leading cardiologists and professionals in cardiology will be discussing the significant benefits of these devices and the latest innovations in heart rhythm management.

DISCLAIMER: Please be informed that in some EU countries (Bulgaria, Cyprus, Estonia, France, Greece, Hungary, Ireland, Italy, Latvia, Lithuania, Luxembourg, Malta, Poland, Portugal, Romania, Slovakia, Belgium, Netherlands, Slovenia and Spain) medical device advertisement to general public is not permitted. Therefore, if you are accessing this website from one of those countries and you are not a healthcare professional, you need to exit this site immediately, since you would be viewing information that may not be legally allowed under the laws of your country of residence. Should you disregard this warning notice, Boston Scientific declines any liability as to your access to your access to such information.

<https://news.bostonscientific.eu/2014-07-11-Boston-Scientific-announces-new-developments-in-its-Electrophysiology-portfolio>